Beam Therapeutics

New Capabilities

Preparing an FDA application for risto-cel

Beam Therapeutics said Tuesday that its sickle cell treatment, risto-cel, met the main goal of a late-stage trial: patients stayed free of severe pain crises for at least 12 months. It is the first positive late-stage result for base editing, a gene-editing method that changes individual DNA letters without cutting the strand. Beam plans to file for FDA approval as early as the end of 2026.

Updated 3 hours ago